研究等業績 - その他 - 成田　伸太郎

秋田大学における転移性副腎腫瘍に対する副腎摘除術の検討

小泉 淳, 井上 高光, 沼倉 一幸, 鶴田 大, 前野 淳, 齋藤 満, 成田 伸太郎, 羽渕 友則

日本内分泌・甲状腺外科学会雑誌 ( 日本内分泌外科学会・日本甲状腺外科学会 )  33 ( Suppl.1 ) S100 - S100   2016年04月

秋田大学における転移性腎細胞癌に対するPazopanibの初期使用経験

喜早 祐介, 井上 高光, 五十嵐 龍馬, 鶴田 大, 斎藤 満, 前野 淳, 成田 伸太郎, 土谷 順彦, 佐藤 滋, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  104回   PP3 - 026   2016年04月

脂肪酸結合タンパク質4の過剰発現と分泌は前立腺癌進行を促進する(Overexpression and secretion of fatty acid binding protein 4 promotes prostate cancer progression)

黄 明国, 成田 伸太郎, 土谷 順彦, 田中 正光, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  104回   PP2 - 100   2016年04月

血清炎症性サイトカイン濃度からみた根治的膀胱全摘術における手術侵襲度の検討

鶴田 大, 齋藤 満, 井上 高光, 成田 伸太郎, 前野 淳, 土谷 順彦, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  104回   PP3 - 218   2016年04月

進行性前立腺癌治療におけるunmet medical needsをいかに埋めるか 若手医師意見の集約 進行性前立腺癌患者に「生活で気をつけることはありますか?」と聞かれたら

成田 伸太郎, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  104回   FS21 - 1   2016年04月

von Recklinghausen病に合併した縦隔原発巨大胚細胞腫の一例

嘉島 相輝, 齋藤 満, 沼倉 一幸, 神田 壮平, 山本 竜平, 高山 孝一朗, 鶴田 大, 秋濱 晋, 井上 高光, 成田 伸太郎, 土谷 順彦, 佐藤 滋, 羽渕 友則, 齋藤 元, 南谷 佳弘

泌尿器外科 ( 医学図書出版(株) )  29 ( 2 ) 186 - 186   2016年02月

ロボット支援手術 その後の展開 秋田大学におけるロボット支援腹腔鏡下根治的膀胱全摘術・腎部分切除術の現状と工夫

齋藤 満, 土谷 順彦, 成田 伸太郎, 井上 高光, 鶴田 大, 秋濱 晋, 佐藤 滋, 羽渕 友則

泌尿器外科 ( 医学図書出版(株) )  29 ( 2 ) 193 - 193   2016年02月

多発肺・肝・骨転移を伴う悪性褐色細胞腫に対しCVD療法が奏功した1例

今村 専太郎, 齋藤 満, 五十嵐 龍馬, 小泉 淳, 高山 孝一朗, 鶴田 大, 秋濱 晋, 井上 高光, 成田 伸太郎, 土谷 順彦, 羽渕 友則, 佐藤 滋, 堀川 洋平, 下田 直威

泌尿器外科 ( 医学図書出版(株) )  29 ( 2 ) 194 - 194   2016年02月

ロボット支援/腹腔鏡下膀胱全摘除術における問題点と対策 ロボット支援腹腔鏡下膀胱全摘術の問題点とその対策

鶴田 大, 井上 高光, 成田 伸太郎, 齋藤 満, 前野 淳, 土谷 順彦, 羽渕 友則

日本内視鏡外科学会雑誌 ( (一社)日本内視鏡外科学会 )  20 ( 7 ) WS12 - 5   2015年12月

ロボット支援腹腔鏡下前立腺全摘除術(RALP)における神経温存が術後尿失禁に及ぼす影響

高山 孝一朗, 土谷 順彦, 鶴田 大, 前野 淳, 齋藤 満, 成田 伸太郎, 井上 高光, 羽渕 友則

日本内視鏡外科学会雑誌 ( (一社)日本内視鏡外科学会 )  20 ( 7 ) OS182 - 8   2015年12月

後期高齢者の浸潤性膀胱癌に対する少量シスプラチン併用放射線療法の効果と忍容性の検討

鶴田 大, 成田 伸太郎, 井上 高光, 齋藤 満, 秋濱 晋, 土谷 順彦, 羽渕 友則

日本老年泌尿器科学会誌 ( 日本老年泌尿器科学会 )  28   46 - 46   2015年12月

Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.

Shintaro Narita, Koji Mitsuzuka, Norihiko Tsuchiya, Takuya Koie, Sadafumi Kawamura, Chikara Ohyama, Tatsuo Tochigi, Takuhiro Yamaguchi, Yoichi Arai, Tomonori Habuchi

International journal of urology : official journal of the Japanese Urological Association   22 ( 11 ) 1029 - 35   2015年11月

OBJECTIVES: To assess the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer patients treated using radical prostatectomy. METHODS: We retrospectively reviewed the medical records of 1268 men with prostate cancer treated using radical prostatectomy without neoadjuvant therapy. The association between various risk factors and biochemical recurrence was then statistically evaluated. The Kaplan-Meier method, log-rank tests and Cox proportional hazards models were used for statistical analysis. RESULTS: In the intermediate-risk group, 96 patients (14.5%) experienced biochemical recurrence during a median follow up of 41 months. In the intermediate-risk group, preoperative prostate-specific antigen level, prostate volume and prostate-specific antigen density were significant preoperative risk factors for biochemical recurrence, whereas other factors including age, primary Gleason 4, clinical stage >T2 and percentage of positive biopsies were not. In multivariate analysis, higher preoperative prostate-specific antigen level and density, and a smaller prostate volume were independent risk factors for biochemical recurrence in the intermediate-risk group. Biochemical recurrence-free survival of patients in the intermediate-risk group with a higher prostate-specific antigen level and density (≥15 ng/mL, ≥0.6 ng/mL/cm(3), respectively), and lower prostate volume (≤10 mL) was comparable with that of high-risk group individuals (P = 0.632, 0.494 and 0.961, respectively). CONCLUSIONS: Preoperative prostate-specific antigen, prostate volume and prostate-specific antigen density are significant risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer patients treated using radical prostatectomy. Using these variables, a subset of the intermediate-risk patients can be identified as having equivalent outcomes to high-risk patients.

DOI PubMed

Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.

Takahiro Kojima, Koji Kawai, Kunihiko Tsuchiya, Takashige Abe, Nobuo Shinohara, Toshiaki Tanaka, Naoya Masumori, Shigeyuki Yamada, Yoichi Arai, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi, Hiroyuki Nishiyama

International journal of urology : official journal of the Japanese Urological Association   22 ( 10 ) 923 - 7   2015年10月

OBJECTIVES: To clarify the significance of the International Germ Cell Cancer Collaborative Group classification in the 2000s, especially in intermediate- and poor-prognosis testicular germ cell tumor in Japan. METHODS: We retrospectively analyzed 117 patients with intermediate- and poor-prognosis testicular non-seminomatous germ cell tumor treated at five university hospitals in Japan between 2000 and 2010. Data collected included age, levels of tumor markers, spread to non-pulmonary visceral metastases, treatment details and survival. RESULTS: The median follow-up period of all patients was 57 months. A total of 50 patients (43%) were classified as having intermediate prognosis, and 67 patients (57%) as poor prognosis according to the International Germ Cell Cancer Collaborative Group classification. As first-line chemotherapy, 92 patients (79%) received bleomycin, etoposide and cisplatin. Of all patients, 74 patients (63%) received second-line chemotherapy. The most commonly used second-line chemotherapy regimens were a combination of taxanes, ifosfamide and platinum in 49 cases (66%). Overall, 33 patients (28%) received third-line chemotherapy. A total of 88 patients (75%) underwent post-chemotherapy surgery. The 5-year overall survival for intermediate (n = 50) and poor prognosis (n = 67) was 89% and 83% (P = 0.21), respectively. In poor prognosis patients, patients with two or more risk factors (any of high lactic dehydrogenase, alpha-fetoprotein and human chorionic gonadotropin levels, and presence of non-pulmonary visceral metastases) had significantly worse survival than those with only one risk factor (71% and 91%, respectively, P = 0.01). CONCLUSIONS: The 5-year overall survivals of poor-prognosis testicular non-seminomatous germ cell tumor patients reached 83%. Further stratification of poor-prognosis patients based on a number of risk factors has the potential to further identify those with poorer prognosis.

DOI PubMed

Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.

Takuya Koie, Koji Mitsuzuka, Takahiro Yoneyama, Shintaro Narita, Sadafumi Kawamura, Yasuhiro Kaiho, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa

International journal of clinical oncology   20 ( 5 ) 1018 - 25   2015年10月

BACKGROUND: The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) in high-risk Pca patients treated with a neoadjuvant therapy comprising a luteinizing-hormone-releasing hormone (LHRH) agonist plus low dose estramustine phosphate (EMP) (LHRH+EMP) followed by radical prostatectomy (RP). In the present study, we used a retrospective design via propensity score matching to elucidate the clinical benefit of neoadjuvant LHRH+EMP for high-risk Pca. METHODS: The Michinoku Urological Cancer Study Group database contained data for 1,268 consecutive Pca patients treated with RP alone at 4 institutions between April 2000 and March 2011 (RP alone group). In the RP alone group, we identified 386 high-risk Pca patients. The neoadjuvant LHRH+EMP group included 274 patients with high-risk Pca treated between September 2005 and November 2013 at Hirosaki University. Neoadjuvant LHRH+EMP therapy included LHRH and EMP administration at a dose of 280 mg/day for 6 months before RP. The outcome measures were overall survival (OS) and BRFS. RESULTS: The propensity score-matched analysis indicated 210 matched pairs from both groups. The 5-year BRFS rates were 90.4 and 65.8 % for the neoadjuvant LHRH+EMP and RP alone groups, respectively (P < 0.0001). The 5-year OS rates were 100 and 96.1 % for the neoadjuvant LHRH+EMP and RP alone groups, respectively (P = 0.110). CONCLUSIONS: Although the present study was not randomized, neoadjuvant LHRH+EMP therapy followed by RP appeared to reduce the risk of biochemical recurrence. A prospective randomized study is warranted to determine the clinical implications of the neoadjuvant therapy described here.

DOI PubMed

前立腺がん進展の分子メカニズムと去勢抵抗性前立腺がんに対する治療戦略 前立腺癌発症・進展における高脂肪食および脂質代謝の役割

成田 伸太郎, 佐々木 雄彦, 羽渕 友則

日本癌学会総会記事 ( 日本癌学会 )  74回   SST8 - 2   2015年10月

アディポネクチンはプログラム細胞死を抑制し、腎癌増殖に関与する

伊藤 隆一, 成田 伸太郎, 黄 明国, 鶴田 大, 前野 淳, 齋藤 満, 井上 高光, 土谷 順彦, 佐藤 滋, 羽渕 友則

日本癌学会総会記事 ( (一社)日本癌学会 )  74回   P - 2139   2015年10月

前立腺がん進展における脂肪酸結合分子4の役割

黄 明国, 小泉 淳, 成田 伸太郎, 土谷 順彦, 田中 正光, 羽渕 友則

日本癌学会総会記事 ( (一社)日本癌学会 )  74回   P - 3259   2015年10月

腎細胞癌進展とインスリンレセプター発現との逆関連

井上 高光, 黄 明国, 鶴田 大, 成田 伸太郎, 土谷 順彦, 羽渕 友則

日本癌学会総会記事 ( (一社)日本癌学会 )  74回   P - 2129   2015年10月

進行性腎細胞癌におけるチロシンキナーゼ阻害薬の長期服用に関連する因子の検討

土谷 順彦, 成田 伸太郎, 井上 高光, 齋藤 満, 前野 淳, 鶴田 大, 高山 孝一朗, 五十嵐 龍馬, 伊藤 隆一, 羽渕 友則

日本癌治療学会誌 ( (一社)日本癌治療学会 )  50 ( 3 ) 1877 - 1877   2015年09月

[PRIMARY MEDIASTINAL GERM CELL TUMOR ARISING IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1].

Soki Kashima, Mitsuru Saito, Norihiko Tsuchiya, Hajime Saito, Hiroshi Nanjo, Kazuyuki Numakura, Hiroshi Tsuruta, Susumu Akihama, Takamitsu Inoue, Shintaro Narita, Yoshihiro Minamiya, Shigeru Satoh, Tomonori Habuchi

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology   106 ( 3 ) 178 - 84   2015年07月

Neurofibromatosis type 1 (NF1) is a distinct genetic disorder due to the NF1 gene mutation which induces the aberrant activation of the RAS-signaling. Because RAS-related proteins function as oncogenic factors, NF1 patients frequently develop malignant tumors, especially of neural crest origin, such as peripheral nerve sheath. In addition, malignant tumors of the pancreas, colorectum, and lung have been reported to frequently arise in NF1 patients. However, the association between germ cell tumor and NF1 has not been clarified yet. A 29-year-old male with dyspnea was referred to our hospital because of the large mass in the anterior mediastinum and cervical lymph node swelling. The diagnosis was extragonadal germ cell tumor with cervical lymph node metastasis, and complete remission was obtained by multidisciplinary treatment consisted of combination chemotherapy and surgical resection. To our acknowledgement, this is the first case of extragonadal germ cell tumor in NF1 patients. We discuss the relevance between activation of the RAS-signaling and the development of germ cell tumor.

PubMed